In AD patients, although no significant increase in [18F]THK5317 binding  was noted at the group level over 17 months, [18F]FDG binding declined in AD-related regions [121, 194], suggesting a spatiotemporal offset between tau pathology and functional changes, possibly dependent on AD severity. Here, MAPT is linked to Alzheimer disease.